Table 1. Clinical significance of VGLL4 expression in CRC.
| Groups |
VGLL4 expression |
n | Positive (%) | Pvalue (Fisher's test) | |||
|---|---|---|---|---|---|---|---|
| − | + | ++ | +++ | ||||
| Sex | |||||||
| Male | 9 | 10 | 12 | 5 | 36 | 75.0 | 1.000 |
| Female | 6 | 6 | 8 | 4 | 24 | 62.5 | |
| Age | |||||||
| <60 | 8 | 7 | 8 | 3 | 26 | 69.2 | 0.7745 |
| >=60 | 7 | 9 | 12 | 6 | 34 | 79.4 | |
| Tumour Size | |||||||
| pT1+pT2 | 4 | 7 | 14 | 7 | 32 | 87.5 | 0.0278* |
| pT3+pT4 | 11 | 9 | 6 | 2 | 28 | 60.7 | |
| Lymph node metastasis | |||||||
| N0+N1 | 5 | 12 | 16 | 7 | 40 | 87.5 | 0.0230* |
| N2+N3 | 10 | 4 | 4 | 2 | 20 | 50.0 | |
| Distant metastasis | |||||||
| M0 | 7 | 10 | 17 | 8 | 42 | 83.3 | 0.0514 |
| M1 | 8 | 6 | 3 | 1 | 18 | 55.5 | |
| Tumour stage | |||||||
| I+II | 4 | 8 | 15 | 6 | 33 | 87.9 | 0.0321* |
| III+IV | 11 | 8 | 5 | 3 | 27 | 59.3 | |
| Total | 15 | 16 | 20 | 9 | 60 | ||
*Statistically significant by using Fisher's exact test, P<0.05.